Epidarex Capital

Harness Therapeutics is a private biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®. This innovative technology allows for the precise upregulation of protein expression, providing a unique mechanism of action for challenging diseases. By significantly expanding the druggable proteome, Harness Therapeutics aims to address conditions that have been difficult to treat with traditional small molecules, biologics, or gene therapies. The company's primary focus is on central nervous system and ophthalmologic disorders, although the potential applications of its platform extend across various therapeutic areas. Harness Therapeutics is committed to meeting unmet medical needs by creating differentiated products that enhance the translation of important, validated neurodegenerative targets.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Harness Therapeutics is a private biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®. This innovative technology allows for the precise upregulation of protein expression, providing a unique mechanism of action for challenging diseases. By significantly expanding the druggable proteome, Harness Therapeutics aims to address conditions that have been difficult to treat with traditional small molecules, biologics, or gene therapies. The company's primary focus is on central nervous system and ophthalmologic disorders, although the potential applications of its platform extend across various therapeutic areas. Harness Therapeutics is committed to meeting unmet medical needs by creating differentiated products that enhance the translation of important, validated neurodegenerative targets.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. By targeting the Kaiser-Meyer-Olkin (KMO) enzyme, the company aims to regulate systemic inflammation and tackle the underlying pathology of various medical conditions. Kynos Therapeutics is dedicated to providing innovative therapies that represent a new generation of potent KMO inhibitors, offering potential solutions in areas where current treatment options are limited.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Dunad Therapeutics is a biopharmaceutical company dedicated to advancing next-generation therapies through targeted protein degradation. The company specializes in developing small molecule platforms designed to induce the degradation of disease-causing proteins, many of which are traditionally considered undruggable. This approach involves directly modulating protein stability and conformation, offering a novel molecular strategy that is both selective and applicable across various target classes. Unlike other technologies in this field, Dunad Therapeutics' method employs a unique mechanism of action, providing a distinct advantage in the development of targeted oral therapies.

Leucid Bio is an innovative biotech company focused on developing advanced cell therapies for refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is led by a team with extensive scientific and commercial expertise. The company specializes in creating novel CAR T-cell therapies designed to deliver improved and more durable responses compared to earlier generations, thereby enhancing treatment outcomes for patients who have exhausted other options. Through its ongoing collaboration with King's College, Leucid Bio has exclusive access to a wealth of scientific, clinical, and manufacturing resources, positioning it at the forefront of immuno-oncology advancements.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

LUNAC Therapeutics is a biotechnology company focused on the development of advanced oral anticoagulant drugs aimed at treating and preventing life-threatening thrombotic events. The company's innovative drug formulations are designed to minimize bleeding risks in patients, allowing healthcare providers to manage high-risk patients with safe dose escalation. By addressing critical needs in anticoagulation therapy, LUNAC Therapeutics seeks to improve patient outcomes and enhance treatment options in the healthcare landscape.

Dunad Therapeutics is a biopharmaceutical company dedicated to advancing next-generation therapies through targeted protein degradation. The company specializes in developing small molecule platforms designed to induce the degradation of disease-causing proteins, many of which are traditionally considered undruggable. This approach involves directly modulating protein stability and conformation, offering a novel molecular strategy that is both selective and applicable across various target classes. Unlike other technologies in this field, Dunad Therapeutics' method employs a unique mechanism of action, providing a distinct advantage in the development of targeted oral therapies.

Slate Bio is an immunotherapeutics development company focused on creating therapies for autoimmune and inflammatory diseases. By utilizing a bifunctional cytokine, the company aims to restore the body's natural immunological response, enhancing antigen expression in genes associated with autoimmune conditions. These innovative therapies provide patients with an independent synergistic pathway that offers greater tissue selectivity and improved pharmacodynamics, allowing for effective treatment at lower doses and with reduced side effects.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, that specializes in developing novel disease-modifying therapeutics aimed at addressing neurodegenerative diseases. Founded in 2019, the company focuses on restoring cellular balance disrupted by these conditions. Its therapeutic platform utilizes distinct molecular approaches to enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Libra Therapeutics targets multiple neurodegenerative disorders, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease, with the intention of offering effective treatments that mitigate the impact of these debilitating ailments.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

LUNAC Therapeutics is a biotechnology company focused on the development of advanced oral anticoagulant drugs aimed at treating and preventing life-threatening thrombotic events. The company's innovative drug formulations are designed to minimize bleeding risks in patients, allowing healthcare providers to manage high-risk patients with safe dose escalation. By addressing critical needs in anticoagulation therapy, LUNAC Therapeutics seeks to improve patient outcomes and enhance treatment options in the healthcare landscape.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

AdoRx Therapeutics Limited is a UK-based drug discovery company founded in 2017, focused on developing new cancer therapeutics by modulating the adenosine pathway. High levels of adenosine in the tumor microenvironment allow cancer cells to evade immune detection, presenting a significant challenge in treatment. AdoRx is dedicated to designing effective adenosine receptor antagonists aimed at counteracting these effects and enhancing the immune response against tumors. The company boasts a leadership team with extensive experience in biotechnology and pharmaceuticals, having discovered over 25 clinical candidates collectively. By concentrating on the adenosine pathway, AdoRx Therapeutics aims to create innovative solutions that improve cancer treatment outcomes.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom, founded in June 2012. The company specializes in the research and development of innovative therapies for dietary-related metabolic diseases, which have been increasingly prevalent in recent decades. Eternygen focuses on developing NaCT inhibitors, targeting the sodium-coupled citrate transporter, a crucial regulator of lipid metabolism implicated in conditions such as fatty liver, diabetes, and obesity. By employing a network of esteemed scientists and contract research organizations, Eternygen aims to create safe and effective treatments that address the underlying metabolic failures associated with these widespread diseases.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Caldan Therapeutics Ltd is a biotechnology company formed as a spinout from the University of Glasgow and the University of Southern Denmark. The company is focused on developing innovative therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases such as Type 2 Diabetes (T2D). The collaboration between Professors Graeme Milligan and Trond Ulven has led to the identification of these receptors as promising targets for addressing various aspects of T2D, including insulin secretion, sensitivity, and cellular protection. In addition to T2D, Caldan Therapeutics is exploring the potential of its technology to treat other conditions, including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Funderbeam is a funding and trading platform established in 2013 that connects companies with investors to facilitate the buying and selling of equity stakes in private companies. It serves as a global data platform for startups, enabling founders to access legal support, funding management, and a network of investors. The platform empowers investors by allowing them to manage their investments and trade at their convenience. Utilizing blockchain technology, Funderbeam enhances its operations by offering a secure ledger for transactions and providing access to private market investment opportunities. The platform allows clients to track their private market portfolios and directly invest in early-stage and growth companies, thereby supporting startups in securing the necessary funding for their development.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Clyde Biosciences, established in 2012 and headquartered in Glasgow, UK, specializes in providing cardiac cell analysis solutions for the pharmaceutical and biotechnology industries, both domestically and internationally. The company's core offerings include cellOPTIQ, an optical action potential assay, and XTENDSR, a solution for measuring drug-induced changes on cardiac sarcoplasmic reticulum function. These tools enable clients to gain insights into the mechanisms and effects of drug compounds on human cells, aiding in the evaluation of drug toxicity and cardiotoxicity risk during the research and development phase.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Sirakoss is a Scotland-based medical device company specializing in the development of synthetic bone graft substitutes. The company focuses on creating innovative solutions for trauma, spine, craniomaxillofacial, and dental applications. Sirakoss utilizes its proprietary MaxSi Graft technology, available in granular and putty forms, to effectively address spinal fusions and bone defects. This technology is designed to aid in the fusion of bones, helping to correct congenital or degenerative conditions, ultimately facilitating faster recovery for patients and promoting a healthier lifestyle.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, specializing in the development of advanced imaging technologies for medical applications. Founded in 2014, the company initially focused on creating fluorescent optical imaging agents to assist in the detection and surgical guidance of cancer. Its flagship product, EMI-137, has successfully progressed through phase 2b clinical trials for colorectal cancer. In 2019, Edinburgh Molecular Imaging transitioned its focus to therapeutics, leveraging its expertise in molecular imaging to develop a systemic radiotheragnostic platform targeting c-Met. This platform includes the investigational agents [Ga68]EMP-10X and [Lu177/Ac225]EMP-10X, which have already shown proof of concept in clinical trials involving patients. The company's team possesses extensive experience in medicinal chemistry, biochemistry, and clinical development, positioning Edinburgh Molecular Imaging as a key player in the advancement of image-guided therapies for cancer diagnosis and treatment.

Leucid Bio is an innovative biotech company focused on developing advanced cell therapies for refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is led by a team with extensive scientific and commercial expertise. The company specializes in creating novel CAR T-cell therapies designed to deliver improved and more durable responses compared to earlier generations, thereby enhancing treatment outcomes for patients who have exhausted other options. Through its ongoing collaboration with King's College, Leucid Bio has exclusive access to a wealth of scientific, clinical, and manufacturing resources, positioning it at the forefront of immuno-oncology advancements.